San Francisco – November 6, 2014 – Cooley advised Atara Biotherapeutics, Inc. on its $63 million initial public offering. Atara is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company now trades on The NASDAQ Global Market under the symbol "ATRA."
Goldman, Sachs & Co. and Citigroup Global Markets Inc. acted as joint book-running managers for the offering, and Jefferies LLC acted as manager for the offering.
The Cooley corporate and securities team advising Atara was comprised of partners Kenneth Guernsey and Jodie Bourdet and associates Carlton Fleming, Robert E. Jones and Eric Cheng.
Critical support was provided by partner Barclay Kamb (life sciences); partner Natasha Leskovsek and associate Bin Wang (health care and life sciences regulatory); partner Bill Christiansen (intellectual property); special counsel Laura McDaniels (compensation and benefits); and partners Susan Cooper Philpot and Bill Morrow (tax).
Thus far in 2014, Cooley has advised on 90 completed public offerings including 46 completed IPOs.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has 800 lawyers across 11 offices in the United States and China.